Innate cellular antiviral defences present a significant challenge to viral vector production and transduction for cell and gene therapy manufacturing. Learn about what they are, the challenges they pose and Virica's solution to mitigating its impact on viral vector yield and quality. View infographic here: Antiviral Defenses: What You Need to Know [...]
Navigating the fast-paced cell and gene therapy landscape? Stay ahead of the curve with our curated news on viral vectors in cell & gene therapy October edition. Read here: Virica's Industry Insights- October Edition
In this interview Jean-Simon Diallo, CEO and Scientific Founder, and JonDavid De Jong, VP Scientific Operations discuss the challenges antiviral defenses pose to the successful production of vaccines and advanced therapies and what Virica is doing to tackle this problem. Check out the interview with BioInsights here! Read full interview: Virica's BioInsights Interview
The impact of innate cellular antiviral defenses has emerged as a crucial area of investigation in viral vector manufacturing. Several recent publications have highlighted that the cell's natural response to the introduction of foreign genetic material can trigger defenses that hinder viral production efficiency. Although there have been any approaches to circumvent these barriers, the [...]
Virica is pleased to announce it is part of the Canadian Pandemic Preparedness Hub (CP2H), a new research hub designed to protect Canadians against future pandemics and emerging threats. This multidisciplinary hub is part of an investment by the Government of Canada to grow a strong and competitive biomanufacturing and life sciences sector. “To continue [...]
Dr. Jean-Simon Diallo, Virica’s Scientific Founder & CEO, attended and presented on the topic “Overcoming barriers in viral vector manufacturing: Small molecule targeting of antiviral defenses” at the recent Cell Culture Engineering conference. Key takeaways noted for Dr. Jean-Simon Diallo were: What was surprising: Several talks made mention of antiviral defenses as an impediment to manufacturing [...]
Ottawa, Canada – April 21, 2023 –Virica Biotech Inc. (“Virica”), a leading supplier and developer of novel viral enhancers, announced today it is expanding its bioprocessing facilities and increasing its capacity to scale up the manufacturing of viral medicines and vaccines. The Government of Ontario is supporting the expansion at sites in Ottawa with a [...]
Ottawa, Canada- January 5th, 2023- Virica Biotech Inc. ("Virica"), a leading supplier and developer of viral enhancers for scaling of viral medicines, announced today that Beth Thompson-Webb will be joining the company as Chief Commercial Officer (CCO), effective January 9, 2023. Based out of Boston, MA, Ms. Thompson-Webb will be leading Virica’s commercial efforts to drive [...]
With the holidays upon us, it is time to reflect on what Virica Biotech has accomplished in 2022, thanks to the hard work of our employees and partners. Read the full letter here.
Virica Biotech Inc. (“Virica”), a leading developer of solutions for scaling of viral medicines, will be featured in a live webinar to be held on Monday, November 14, 2022, at 2:30pm EST. This webinar will focus on process intensification in the manufacturing of adeno associated virus (AAV) vectors. Tune into this free webinar to learn [...]
